RSC Advances

CORRECTION

Cite this: *RSC Adv.*, 2021, **11**, 20003

Correction: Characterization of an exopolysaccharide from probiont *Enterobacter faecalis* MSI12 and its effect on the disruption of *Candida albicans* biofilm

G. Seghal Kiran,[a] S. Priyadharshini,[a] K. Anitha,[a] Elumalai Gnanamani[b] and Joseph Selvin*[c]

DOI: 10.1039/d1ra90123k

rsc.li/rsc-advances

Correction for 'Characterization of an exopolysaccharide from probiont *Enterobacter faecalis* MSI12 and its effect on the disruption of *Candida albicans* biofilm' by G. Seghal Kiran *et al.*, *RSC Adv.*, 2015, **5**, 71573–71585, DOI: 10.1039/C5RA10302A.

The authors regret that incorrect versions of Fig. 7 and 8 were included in the original article. The correct versions of Fig. 7 and 8 are presented below with updated captions.

Accordingly, the experimental methods followed in the phase contrast microscopy and large-size images of Fig. 7 have been provided in the ESI. The ESI has been updated online to reflect this change.

[a]*Department of Food Science and Technology, Pondicherry University, Puducherry – 605014, India. E-mail: seghalkiran@gmail.com*

[b]*Department of Chemistry, Stanford University, Stanford, USA. E-mail: gnanam@stanford.edu*

[c]*Department of Microbiology, School of Life Sciences, Pondicherry University, Puducherry – 605014, India. E-mail: josephselvinss@gmail.com; jselvin.mib@pondiuni.edu.in; Fax: +91-413-2655358; Tel: +91-413-2655358*



Fig. 7 Phase contrast micrographs showing biofilm disruption potential of MSI12-EPS on *C. albicans*. The *C. albicans* biofilm was developed on a cover glass and then it was treated with varying concentrations of EPS and fluconazole ranging from 50–250 μg. The treated cover glass was stained with crystal violet and observed under a phase-contrast microscope (Nikon) at ×40 magnification. A – Control biofilm, B1 – 50 mg fluconazole, B2 – 50 μg MSI12-EPS, C1 – 100 mg fluconazole, C2 – 100 μg MSI12-EPS, D1 – 150 mg fluconazole, D2 – 150 μg MSI12-EPS, E1 – 200 mg fluconazole, E2 – 200 μg MSI12-EPS and F1 – 250 mg fluconazole, F2 – 250 μg MSI12-EPS. The images were recorded using a uniform scale of 10 μm which is shown in the image panels.



Fig. 8 Confocal laser scanning micrographs showing biofilm disruption potential of MSI12-EPS on *C. albicans*. The pre-formed biofilm was treated for 24 h with EPS and fluconazole of varying concentrations ranging from 50–250 μg. Untreated biofilms were used as controls and the biofilm coverage thus formed on glass slides were stained with 0.1% acridine orange and subjected to visualization in a CLSM (LSM 710, Carl Zeiss). A – Control biofilm, B1 – 50 mg fluconazole, B2 – 50 μg MSI12-EPS, C1 – 100 mg fluconazole, C2 – 100 μg MSI12-EPS, D1 – 150 mg fluconazole, D2 – 150 μg MSI12-EPS, E1 – 200 mg fluconazole, E2 – 200 μg MSI12-EPS and F1 – 250 mg fluconazole, F2 – 250 μg MSI12-EPS.

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.